Ubs Group Ag Novo Nordisk A S Call Options Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$119.07 - $145.42 $1.84 Million - $2.25 Million	-15,482 Reduced 77.41%	4,518 $537,000
Q2 2024 Aug 13, 2024	SELL	$122.71 - $146.91 $2.15 Million - $2.57 Million	-17,500 Reduced 46.67%	20,000 $2.85 Million
Q1 2024 May 13, 2024	SELL	$102.11 - $135.92 $21.2 Million - $28.2 Million	-207,288 Reduced 84.68%	37,500 $4.82 Million
Q4 2023 Feb 09, 2024	BUY	$87.78 - $105.45 $21.5 Million - $25.8 Million	244,788 New	244,788 $25.3 Million
Q4 2021 Feb 14, 2022	BUY	$95.88 - $117.08 $5.36 Million - $6.54 Million	55,900 Added 698.75%	63,900 $7.16 Million
Q1 2020 May 01, 2020	SELL	$49.46 - $64.78 $2.87 Million - $3.76 Million	-58,100 Reduced 87.9%	8,000 $482,000
Q4 2018 Feb 14, 2019	BUY	$41.54 - $47.25 $1.79 Million - $2.03 Million	43,000 Added 186.15%	66,100 $3.05 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $3.17 Million - $3.47 Million	-67,800 Reduced 74.59%	23,100 $1.09 Million
Q4 2017 Feb 14, 2018	BUY	$47.53 - $53.73 $4.32 Million - $4.88 Million	90,900	90,900 $4.88 Million

1,957

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $192B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.